Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.
Identifieur interne : 002480 ( Main/Curation ); précédent : 002479; suivant : 002481Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.
Auteurs : Andis Klegeris [Canada] ; Patrick L. McgeerSource :
- Biochemical and biophysical research communications [ 0006-291X ] ; 2007.
English descriptors
- KwdEn :
- MESH :
- chemical , chemistry : Amyloid, Complement System Proteins, Immunoglobulin G, alpha-Synuclein.
- Binding Sites, Complement Activation, Islet Amyloid Polypeptide, Protein Binding.
Abstract
Complement can damage host tissue when overactivated. Evidence of complement self damage exists for Alzheimer disease (AD), age-related macular degeneration, type 1 diabetes mellitus (T1DM), and Parkinson disease (PD). Known complement activators include Abeta, found in AD, and IgG found in T1DM. We compared their complement activating ability in vitro with those of islet amyloid polypeptide (IAPP), which aggregates in the pancreas of T2DM, and alpha-synuclein (alpha-Syn), which aggregates in PD. We found that IAPP and the alternatively spliced alpha-Syn 112 form, but not full-length alpha-Syn 140, activated complement in vitro. Complement activation may contribute to death of insulin-secreting cells in T2DM or to neuronal death in Parkinson disease (PD) and related synucleinopathies where alpha-Syn 112 occurs. This suggests the possibility of anti-inflammatory treatment in these pathologies. It also suggests that blockers of complement activation may be an appropriate therapeutic target for a range of age-related degenerative diseases.
DOI: 10.1016/j.bbrc.2007.04.055
PubMed: 17459337
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001066
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001066
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001066
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000761
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000761
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000761
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002716
Links to Exploration step
pubmed:17459337Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.</title><author><name sortKey="Klegeris, Andis" sort="Klegeris, Andis" uniqKey="Klegeris A" first="Andis" last="Klegeris">Andis Klegeris</name><affiliation wicri:level="1"><nlm:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17459337</idno><idno type="pmid">17459337</idno><idno type="doi">10.1016/j.bbrc.2007.04.055</idno><idno type="wicri:Area/PubMed/Corpus">001066</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001066</idno><idno type="wicri:Area/PubMed/Curation">001066</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001066</idno><idno type="wicri:Area/PubMed/Checkpoint">001066</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001066</idno><idno type="wicri:Area/Ncbi/Merge">000761</idno><idno type="wicri:Area/Ncbi/Curation">000761</idno><idno type="wicri:Area/Ncbi/Checkpoint">000761</idno><idno type="wicri:doubleKey">0006-291X:2007:Klegeris A:complement:activation:by</idno><idno type="wicri:Area/Main/Merge">002716</idno><idno type="wicri:Area/Main/Curation">002480</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.</title><author><name sortKey="Klegeris, Andis" sort="Klegeris, Andis" uniqKey="Klegeris A" first="Andis" last="Klegeris">Andis Klegeris</name><affiliation wicri:level="1"><nlm:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3.</nlm:affiliation><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="ISSN">0006-291X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amyloid (chemistry)</term><term>Binding Sites</term><term>Complement Activation</term><term>Complement System Proteins (chemistry)</term><term>Immunoglobulin G (chemistry)</term><term>Islet Amyloid Polypeptide</term><term>Protein Binding</term><term>alpha-Synuclein (chemistry)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Amyloid</term><term>Complement System Proteins</term><term>Immunoglobulin G</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Binding Sites</term><term>Complement Activation</term><term>Islet Amyloid Polypeptide</term><term>Protein Binding</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Complement can damage host tissue when overactivated. Evidence of complement self damage exists for Alzheimer disease (AD), age-related macular degeneration, type 1 diabetes mellitus (T1DM), and Parkinson disease (PD). Known complement activators include Abeta, found in AD, and IgG found in T1DM. We compared their complement activating ability in vitro with those of islet amyloid polypeptide (IAPP), which aggregates in the pancreas of T2DM, and alpha-synuclein (alpha-Syn), which aggregates in PD. We found that IAPP and the alternatively spliced alpha-Syn 112 form, but not full-length alpha-Syn 140, activated complement in vitro. Complement activation may contribute to death of insulin-secreting cells in T2DM or to neuronal death in Parkinson disease (PD) and related synucleinopathies where alpha-Syn 112 occurs. This suggests the possibility of anti-inflammatory treatment in these pathologies. It also suggests that blockers of complement activation may be an appropriate therapeutic target for a range of age-related degenerative diseases.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002480 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002480 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:17459337
|texte= Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:17459337" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |